MesoTV | What happens when we combine chemotherapy with immunotherapy to treat mesothelioma?

Separately, chemotherapy and immunotherapy are both approved to treat mesothelioma, and individually they work equally well for those patients with the epithelioid type of disease. Currently, the question in front of scientists is what happens when those two treatments are combined?

DREAMER, a new clinical trial enrolling right now in the United States and Australia, is looking to find those answers. In this episode of MesoTV we talk with one of the principal investigators of this study, Dr. Patrick Forde of Johns Hopkins, to ask him about what this trial means to patients. If a patients is considering enrolling in this trial, they should watch this episode.

The interview is moderated by Shannon Sinclair, RN, BSN, OCN, the oncology nurse at the Mesothelioma Applied Research Foundation. www.curemeso.org